Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity persistence of recombinant bivalent HPV (types 16,18) vaccine (Escherichia coli) in 9–17-year-old females
CTR20231470Phase 4Active
- Sponsor
- Xiamen University
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus bivalent (types 16, 18) vaccine in HPV16 infection (HPV16), human papillomavirus infection type 18, Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), HPV-related anogenital disease (HPV-AGD), sponsored by Xiamen University. Started Feb 2021; status: active.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccine
03
Conditions
HPV16 infection (HPV16)human papillomavirus infection type 18Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)HPV-related anogenital disease (HPV-AGD)
Beyond the preview
Go deeper on CTR20231470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231470.